Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 1;52(4):e161-e181.
doi: 10.1097/CCM.0000000000006174. Epub 2024 Jan 19.

Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Children and Adults 2024

Affiliations

Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Children and Adults 2024

Kimia Honarmand et al. Crit Care Med. .

Abstract

Rationale: Maintaining glycemic control of critically ill patients may impact outcomes such as survival, infection, and neuromuscular recovery, but there is equipoise on the target blood levels, monitoring frequency, and methods.

Objectives: The purpose was to update the 2012 Society of Critical Care Medicine and American College of Critical Care Medicine (ACCM) guidelines with a new systematic review of the literature and provide actionable guidance for clinicians.

Panel design: The total multiprofessional task force of 22, consisting of clinicians and patient/family advocates, and a methodologist applied the processes described in the ACCM guidelines standard operating procedure manual to develop evidence-based recommendations in alignment with the Grading of Recommendations Assessment, Development, and Evaluation Approach (GRADE) methodology. Conflict of interest policies were strictly followed in all phases of the guidelines, including panel selection and voting.

Methods: We conducted a systematic review for each Population, Intervention, Comparator, and Outcomes question related to glycemic management in critically ill children (≥ 42 wk old adjusted gestational age to 18 yr old) and adults, including triggers for initiation of insulin therapy, route of administration, monitoring frequency, role of an explicit decision support tool for protocol maintenance, and methodology for glucose testing. We identified the best available evidence, statistically summarized the evidence, and then assessed the quality of evidence using the GRADE approach. We used the evidence-to-decision framework to formulate recommendations as strong or weak or as a good practice statement. In addition, "In our practice" statements were included when the available evidence was insufficient to support a recommendation, but the panel felt that describing their practice patterns may be appropriate. Additional topics were identified for future research.

Results: This guideline is an update of the guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. It is intended for adult and pediatric practitioners to reassess current practices and direct research into areas with inadequate literature. The panel issued seven statements related to glycemic control in unselected adults (two good practice statements, four conditional recommendations, one research statement) and seven statements for pediatric patients (two good practice statements, one strong recommendation, one conditional recommendation, two "In our practice" statements, and one research statement), with additional detail on specific subset populations where available.

Conclusions: The guidelines panel achieved consensus for adults and children regarding a preference for an insulin infusion for the acute management of hyperglycemia with titration guided by an explicit clinical decision support tool and frequent (≤ 1 hr) monitoring intervals during glycemic instability to minimize hypoglycemia and against targeting intensive glucose levels. These recommendations are intended for consideration within the framework of the patient's existing clinical status. Further research is required to evaluate the role of individualized glycemic targets, continuous glucose monitoring systems, explicit decision support tools, and standardized glycemic control metrics.

PubMed Disclaimer

Conflict of interest statement

Dr. Umpierrez’s institution received funding from Dexcom, Abbott, Bayer, and Astra Zeneca. Dr. Sirimaturos’ institution received funding from Grifols; he received funding from Astra Zeneca. Dr. Mechanick received funding from Abbott Nutrition, Aveta.Life, and Twin Health. Dr. Irving disclosed that she is a board member of the American Society for Parenteral and Enteral Nutrition and a member of American Society for Parenteral and Enteral Nutrition/Society of Critical Care Medicine Pediatric Critical Care Nutrition Guideline. Dr. Preiser received funding from Edwards, Glysure, Medtronic, and Optiscan. Dr. Krinsley received funding from Dexcom. Dr. Sands received funding from BioXcel Therapeutics. Dr. Jacobi disclosed that she was an Advisory Board Member of the Pfizer Hospital Business Unit. Dr. Agus’ institution received funding from the National Institutes of Health; he disclosed that Dexcom is providing in kind support with continuous glucose monitors for a clinical trial in children. The remaining authors have disclosed that they do not have any potential conflicts of interest. The total multiprofessional task force of 22, consisting of clinicians and patient/family advocates, and a methodologist applied the processes described in the ACCM guidelines standard operating procedure manual to develop evidence-based recommendations in alignment with the Grading of Recommendations Assessment, Development, and Evaluation Approach (GRADE) methodology. Conflict of interest policies were strictly followed in all phases of the guidelines, including panel selection and voting.

References

    1. van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359–1367
    1. Finfer S, Chittock DR, Su SY, et al.; NICE-SUGAR Study Investigators: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283–1297
    1. Fong KM, Au SY, Ng GWY: Glycemic control in critically ill patients with or without diabetes. BMC Anesthesiol 2022; 22:227
    1. Jacobi J, Bircher N, Krinsley J, et al.: Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med 2012; 40:3251–3276
    1. El-Sayed NA, Aleppo G, Aroda VR, et al.; on behalf of the American Diabetes Association: Diabetes care in the hospital: Standards of care in diabetes—2023. Diabetes Care 2023; 46:S267–S278

Publication types